Clinical Trial Update: Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Bryostatin-1 was studied in patients with relapsed multiple myeloma. The Phase 2 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Bryostatin-1 (bryostatin-1)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED